title: Second primary malignancies and myeloma therapy: fad or fact?
abstract: The risk adaptive therapy approach within low risk patients may involve limiting post-transplant IMiD exposure in patients who have a higher potential for SPM development. It may well be that we are looking at the tip of the iceberg in the year 2012 and SPMs may emerge as an important long-term sequela with further follow-up.
authors.forename: Saad Z
authors.initials: SZ
authors.lastname: Usmani
mesh_terms: D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000209:etiology*; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide